The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs, for the second annual round of drug price negotiations, made possible through the Inflation Reduction Act (IRA).

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.